This CME program, derived from content presented at the Pre-ACTRIMS Advanced Curriculum for Multiple Sclerosis 2023 CME Course in San Diego, California, will highlight the use of anti-CD19 therapeutics to manage patients with anti-AQP4 antibody positive neuromyelitis optica spectrum disorder (NMOSD). The expert faculty, Prof. Hans-Peter Hartung, will first analyze the methodologies for a timely and accurate diagnosis of NMOSD. Next, Prof. Hartung will review recent data for neuromyelitis optica (NMO) therapeutics. Following, he will assess most current and effective treatment plans to improve outcomes in patients with anti-AQP4 antibody positive NMOSD. Upon completion of this activity, learners will gain a better understanding of how to utilize anti-CD19 therapeutics to manage patients with anti-AQP4 antibody positive NMOSD.
Neurologists and other healthcare professionals involved in the management of patients with NMOSD
I. Practical Strategies for Timely and Accurate Diagnosis of NMOSD
II. Clinical Trial Update for NMOSD Therapeutics, Including Anti-CD19 B Cell Depleters for Patients with Anti-AQP4 Antibody Positive NMOSD
III. Current and Effective Treatment Plans to Improve Outcomes in Patients with Anti-AQP4 Antibody Positive NMOSD
- Review the methodologies for a timely and accurate diagnosis of NMOSD
- Analyze recent data for NMO therapeutics, including anti-CD19 B cell depleters for patients with anti-AQP4 antibody positive NMOSD
- Become aware of the most current and effective treatment plans to improve outcomes in patients with anti-AQP4 antibody positive NMOSD
Fred D. Lublin, MD
Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Icahn School of Medicine at Mount Sinai
New York, NY
Hans-Peter Hartung, MD, PhD
Professor, Department of Neurology
Heinrich-Heine-University, Düsseldorf, Germany
Honorary Professor, Brain and Mind Center
University of Sydney, NSW, Australia
Disclosures of Relevant Financial Relationships
It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships relating to the topics of this educational activity. Any relevant financial relationships are mitigated via a content review by planning committee members and faculty with no relevant financial relationships.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
|Faculty||Relationship Identified With:|
|Fred D. Lublin, MD
|Consultant/Advisor: Acorda Therapeutics; Actelion/Janssen; Avotres; Baim Institute; Banner Life Sciences; Biogen; Brainstorm Cell Therapeutics; Bristol-Myers Squibb; EMD Serono; Entelexo Biotherapeutics; Hexal/Sandoz; Horizon Therapeutics; Immunic; Jazz Pharmaceuticals; LabCorp; Mapi Pharma; Mylan; Neuralight; Neurogene; Novartis; Population Council; Sanofi/Genzyme; SetPoint Medical; Sudo Biosciences; Receptos/Celgene; Roche/Genentech; Teva; Viela Bio
Grant/Research Support: Actelion; Brainstorm Cell Therapeutics; Biogen; NMSS; NIH; Novartis; Sanofi
Speaker’s Bureau: Biogen; Janssen Global Services, LLC; Sanofi
Stock Options: Avotres, Entelexo; Neuralight
|Hans-Peter Hartung, MD, PhD||
Consultant/Advisor:Bayer Healthcare; Biogen; GeNeuro; Horizon Therapeutics; Merck; Novartis; Sanofi; TG Therapeutics
Planners and Peer Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC, Chelsey Simonds and Nicole McMenamin hereby state that they or their spouse/life partner do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM.
Clinicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been supported by an independent educational grant from Horizon Therapeutics.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Horizon Therapeutics do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Learners who receive a grade of 66% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
- CME and CNE credit will be issued appropriate certificate of completion.
- Others may request a “certificate of completion”.
- Learners should claim only the credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs
For all CE inquiries or special needs, please contact [email protected].